SCHEMBL16184718

SCHEMBL16184718

COc1cc(-c2cccc(F)c2)cc2c(N3CC(OC)C3)nc(-c3cccnc3)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ GBA1 P04062 3/20 0.41
▸ TTK P33981 2/20 0.39
▸ PDE2A O00408 5/20 0.39
▸ PDE10A Q9Y233 5/20 0.39
▸ PDE5A O76074 4/20 0.39
▸ PDE11A Q9HCR9 4/20 0.39
▸ PIK3CD O00329 1/20 0.38
▸ PIK3R1 P27986 1/20 0.38
▸ PDE4A P27815 1/20 0.38
▸ LMNA P02545 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ CLK4 Q9HAZ1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184801 0.95 MAPT (0.44) MAPTALDH1A1GAAGBA1TTK
SCHEMBL16184060 0.92 MAPT (0.43) MAPTALDH1A1GAAGBA1TTK
SCHEMBL14475241 0.90 MAPT (0.42) MAPTALDH1A1GAAGBA1TTK
SCHEMBL14474741 0.89 MAPT (0.41) MAPTALDH1A1GAAGBA1TTK
SCHEMBL14474744 0.89 MAPT (0.41) MAPTALDH1A1GAAGBA1TTK
SCHEMBL16184054 0.88 ALDH1A1 (0.47) MAPTALDH1A1GAAGBA1PDE2A
SCHEMBL16184706 0.88 ALDH1A1 (0.49) MAPTALDH1A1GAAGBA1PDE2A
SCHEMBL14475266 0.88 MAPT (0.41) MAPTALDH1A1GAAGBA1TTK
SCHEMBL16184712 0.87 ALDH1A1 (0.51) MAPTALDH1A1GAAGBA1PDE2A
SCHEMBL16184724 0.87 MAPT (0.48) MAPTALDH1A1GAAGBA1PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB MAPT 509/4885ALDH1A1 1687/4885GAA 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback